EL SEGUNDO, Calif., Dec. 15 DaVita Inc.(NYSE: DVA), today announced that it is working with the U.S. Department ofHealth and Human Services, Office of Inspector General ("OIG") to respond to asubpoena request for documents issued in connection with the civilinvestigation by the Department of Justice and the U.S. Attorney's Office forthe Northern District of Georgia previously reported in the Company'sQuarterly Report on 10-Q for the period ended September 30, 2008. Thesubpoena was sent from the OIG's office in Atlanta, Georgia and was receivedby the Company on December 12, 2008. The subpoena applies to the Company andits subsidiaries and covers a time period from January 1, 2003 to the present.In response to the subpoena, DaVita will produce a wide range of documentsrelating to the pharmaceutical products Zemplar, Hectorol, Venofer, Ferrlicit,and Epogen. The Company intends to meet with representatives of thegovernment to discuss the scope of the subpoena and the production ofresponsive documents.
To the Company's knowledge, no proceedings have been initiated against theCompany at this time, although the Company cannot predict whether or whenproceedings might be initiated. The Company intends to cooperate with thegovernment's investigation.
"DaVita has been involved in several investigations over the last 9 years,including some covering issues that are repeated in this subpoena. We respectthe government's need to ensure the appropriateness of healthcare providerpractices, especially during times when pharmaceutical issues involvesignificant expense for Medicare. We look forward to meeting with governmentrepresentatives on this new investigation and once again demonstrating thestrength of our clinical outcomes and the integrity and comprehensiveness ofDaVita's Compliance programs," said LeAnne Zumwalt, spokesperson for DaVita.
DaVita is a leading provider of kidney care in the United States,providing dialysis services and education for patients with chronic kidneyfailure and end stage renal disease. DaVita manages more than 1,400 outpatientfacilities and acute units in more than 700 hospitals located in 43 states andthe District of Columbia, serving approximately 110,000 patients.
SOURCE DaVita Inc.